5-alpha-reductase-inhibitors for the treatment of benign prostatic hyperplasia;Der Einfluss der 5-alpha-Reduktase-Inhibitoren auf die benigne Prostatahyperplasie

Wiener Medizinische Wochenschrift

Volumn 146, Issue 8, 1996, Pages 165-168

  Djavan, B ^a   McConnell, J ^b  

^a Urologische Universitatsklinik   (Austria)

^b UNIVERSITY OF DALLAS   (United States)

Author keywords

5 alpha reductase; benign prostatic hyperplasia (BPH); dihydrotestosterone

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

DRUG EFFICACY; MALE; PROSTATE HYPERTROPHY; SHORT SURVEY;

AGED; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS; TESTOSTERONE 5-ALPHA-REDUCTASE; TREATMENT OUTCOME;

EID: 0030003377     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (21)

1. Brooks JR, Herman C, Glitzer MS, Gordon LR, Primka RL, Reynolds GF, Rasmusson GH: Effect of a new 5-alphareductase inhibitor on size, histological characteristics, and androgen concentrations of the canine prostate. Prostate 1982;3:35.
2. Brooks JR, Berman C, Garnes D, Gitinan D, Gordon LR, Malatesta PF, Primka RL, Reynolds GF, Rasmusson GH: Prostatic effects induced in dogs by chronic or acute oral administration of 5-alpha-reductase inhibitors. Prostate 1986;9:65.
3. Cabot AT: The question of castration for enlarged prostate. An Surg 1896;24:265-269.
4. Forti G, Salerno R, Moneti G, Zoppi S, Fiorelli G, Marioni T, Natali A, Constantini A, Serio M, Martini L, Motta M: Three months treatment with a long acting gonadotropine releasing hormone agonist of patients with benign prostatic hyperplasia: effects of tissue androgen concentration, 5-alpha-reductase activity and androgen receptor contents. J Clin Endocrinol Metab 1989;68:461-468.
5. George FW, Johnson L, Wilson JD: The effect of a 5-alpha-reductase inhibitor on androgen physiology in the immature male rate. Endocrinology 1989;125:2434-2438.
6. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BK, Tenover JS: The finasteride study group: The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992;327:1184-1191.
7. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE: Steroid 5-alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974;186:1213.
8. Imperato-McGinley J, Peterson RE, Gautier T, Sturla A: Male pseudohermaphroditism secondary to 5-alpha-reductase deficiency: a model for the role of androgens in both the development of the male phenotype and the evolution of a male gender identity. J Steroid Biochem 1979;11:637-645.
9. Lepor H, Stoner E: Long-term results of medical therapies for benign prostatic hyperplasia. Curr Opin Urol 1995;5:18-24.
10. McConnell JD: The pathophysiology of benign prostatic hyperplasia. J Androl 1991;12:356-363.
11. Mocellini AI, Gardiner R, Marshall V, Johnson W, Bartsch G, Schmidbauer CP, Mossing H, van Cangh PJ, Denis LJ, Arap S, et al: Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993;22:291-299.
12. Monda JM, Oesterling JE: Medical treatment of benign prostatic hyperplasia: 5-alpha-reductase inhibitors and alpha-adrenergic antagonists. Mayo Clin Proc 1993;68:670-679.
13. Peters CA, Walsh PC: The effect of nafareline acetate, a luteinizing-hormone releasing-hormone agonist, on benign prostatic hyperplasia: N Engl J Med 1987;317:599-604.
14. Russel DW, Wilson JD: Steroid 5-alpha-reductase: two genes/two enzymes. Ann Rev Biochem 1994;63:25-61.
15. Schröder FH, Westerhof M, Bosch RJ, Kurth KH: Benign prostatic hyperplasia treated by castration or with the LHRH analogue buserelin: a report of 6 cases. Eur Urol 1986;12:318-321.
16. Stoner E: Three-year safety and efficacy data on the use of finasteride in the treatment of benign hyperplasia. Urology 1994;43: 284-294.
17. Stoner E: Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. Arch Intern Med 1994;154:83-88.
18. Tammela T, Kontturi M: Urodynamic effects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia. J Urol 1993;149:343-344.
19. Thigpen AE, Russell DW: Four amino acid segment in steroid 5-alpha-reductase 1 confers sensitivity to finasteride, a competitive inhibitor. J Biol Chem 1992;267:8577-8583.
20. Walsh PC, Madden JD, Harrod MJ, Goldstein JL, MacDonald PC, Wilson JD: Familial incomplete male pseudohermaphroditism type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadia. N Engl J Med 1974;291:944-949.
21. White JW: The results of double castration in hypertrophy of prostate. Ann Surg 1895;22:1-8.